Aroa Biosurgery Ltd (ASX: ARX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Aroa Biosurgery Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$183.33 million
P/E Ratio
48.61
Dividend Yield
0.00%
Shares Outstanding
350.66 million
Earnings per share
0.011
Dividend per share
N/A
Year To Date Return
-29.05%
Earnings Yield
2.06%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Aroa Biosurgery Ltd (ASX: ARX)
Latest News
Share Gainers
Aroa Biosurgery (ASX:ARX) share price rises on results and strong guidance
ASX Share Market News
Why the Aroa Biosurgery (ASX:ARX) share price is lifting today
Healthcare Shares
How do Avita Medical (ASX:AVH) shares stack up against Polynovo and Aroa Biosurgery?
Healthcare Shares
The Aroa (ASX:ARX) share price has surged 60% since its IPO
ASX Share Market News
Brace for an IPO resurgence as new floats beat the ASX 200 by ~50%
Share Fallers
Why Aroa Biosurgery, Straker, Virgin Money, & Whitehaven shares are dropping lower
⏸️ ASX Shares
Leading fund managers name 4 small cap ASX shares to buy
ASX Share Market News
Aroa Biosurgery share price jumps 8% on approvals
ASX Share Market News
Aroa Biosurgery surges 80% on ASX IPO. Is it still good value?
Frequently Asked Questions
-
No, Aroa Biosurgery does not pay shareholder dividends at this time.
-
Aroa Biosurgery Ltd listed on the ASX on 24 July 2020.
ARX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Aroa Biosurgery Ltd
Aroa Biosurgery Ltd (ASX: ARX) is a New Zealand-based biomedical company specialising in soft tissue regeneration. It develops, manufactures, and distributes medical and surgical products to improve the healing of complex wounds and soft tissue reconstruction.
The company's principal market is the United States where it markets four key products targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
Its first wound-healing product Endoform was approved by the US Food & Drug Administration (FDA) in 2013. Aroa's first commercial surgical product, a reinforced bioscaffold developed in collaboration with US company Tela Bio Inc., was approved by the FDA in 2014.
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 26 Aug 2026 | Brian Ward | Issued | 377,742 | $211,535 |
Issue of securities. 377,742 - Restricted Stock Units
|
| 26 Aug 2026 | Brian Ward | Issued | 726,559 | $406,873 |
Issue of securities. 2,739,683 - Rights
|
| 30 Jun 2026 | Brian Ward | Expiry | 453,206 | $269,657 |
Options expired.
|
| 26 Jun 2026 | John Diddams | Sell | 200,000 | $125,789 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Philip John McCaw | Non-Executive Director | Mar 2008 |
Mr McCaw is a venture capital investor with experience in technology companies. He was Executive Chair and CEO of Docuvera, a software company providing component authoring solutions for pharmaceutical companies. He served on the New Zealand Government's Start Up Advisors Council, which was established to identify opportunities and challenges facing high-growth start-up businesses. Phil has experience investing in and supporting the growth of technology companies and has served as Chair of the Angel Association of New Zealand. Prior to this, he worked with Deloitte Consulting in New Zealand and the United States. He is a member of the Risk Committee.
|
| Mr Paul N Shearer | Non-Executive Director | Oct 2025 |
Mr Shearer has healthcare industry experience, including leadership roles in sales and marketing. He held the position of Senior Vice President - Sales and Marketing at Fisher and Paykel Healthcare. Prior to this, he held roles at ICL Limited and Computercorp Limited.
|
| Mr James (Jim) Neil McLean | Non-Executive ChairmanNon-Executive Director | Aug 2011 |
Mr McLean has experience serving as a chair, director, and executive of research and technology businesses for commercial and New Zealand government organisations. He was Chair of the New Zealand Institute of Plant and Food Research and its predecessor HortResearch and served on the board of the Foundation for Research, Science, and Technology, including five years as Deputy Chair. Before specialising in science and technology businesses, he held management positions with an international manufacturing business and was a partner at EY, where his work focused on business strategy, including a secondment to EY's Washington DC office. He is a member of the risk committee.
|
| Mr Brian Roderick Ward | Chief Executive OfficerManaging Director | Sep 2007 |
Mr Ward is the founder of AROA and has held senior corporate roles in life sciences and healthcare companies. He has management experience across clinical, technical, sales, marketing, corporate development and strategy functions, having worked for multinational organisations including Baxter, Beecham and SmithKline Beecham. He has managed investments in New Zealand technology companies for the Foundation for Research, Science and Technology, served as the founding CEO of NZBio, and has served on government and industry panels. He has led AROA's growth since its establishment.
|
| Dr Catherine Mohr | Non-Executive Director | Nov 2022 |
Dr Mohr has experience across engineering, healthcare, alternative energy, aerospace and entrepreneurship. Her background includes medical technology product research and development, regulatory approvals, product commercialisation and surgical technology. She has held senior strategy and medical research roles and co-founded VeriSure, where she developed the LapCap, a laparoscopic surgery product. She has experience in medical technology innovation and the development of healthcare products.
|
| Ms Darla Hutton | Non-Executive Director | Mar 2024 |
Ms Hutton has medical technology experience across commercial strategy, operations, sales, marketing, healthcare analytics, lean and enterprise consulting. She has held a range of commercial leadership roles, including Regional Sales Director, Vice President of Corporate Accounts, and Vice President of Marketing, Market Access and Custom Hospital Analytics. She has worked in medical technology, pharmaceutical and biotechnology organisations, including Boston Scientific and GlaxoSmithKline, and began her career in the cardiac-thoracic nursing field.
|
| Ms Tracy Weimar | Joint Company Secretary | Jul 2020 |
-
|
| Mr James Blair Agnew | Chief Financial OfficerJoint Company Secretary |
-
|
|
| James Blair Agnew | Chief Financial OfficerJoint Company Secretary |
-
|
|
| Yasmin Winchester | Chief of Technical Operations |
-
|
|
| Rod Stanley | Chief Operating Officer |
-
|
|
| Dr. Barnaby May | Chief Scientific Officer |
-
|
|
| Tracy Weimar | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 51,088,590 | 14.77% |
| J P Morgan Nominees Australia Pty Limited | 46,801,027 | 13.53% |
| Brian Ward and Dr Tracey Ward & Mr Thomas Ward <Arawai No2 A/C> | 33,125,800 | 9.58% |
| Phil Mccaw <Msyth Capital Invest A/C> | 19,597,251 | 5.67% |
| Citicorp Nominees Pty Limited | 18,382,936 | 5.31% |
| BNP Paribas Noms (Nz) Ltd | 15,139,248 | 4.38% |
| Richard Abbott <Jester 002 Investment A/C> | 13,043,020 | 3.77% |
| Mirrabooka Investments Limited | 12,641,127 | 3.65% |
| Aspire Nz Seed Fund Ltd | 10,421,614 | 3.01% |
| BNP Paribas Noms Pty Ltd | 6,403,541 | 1.85% |
| K One W One (No 3) Ltd | 5,882,550 | 1.70% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 4,392,326 | 1.27% |
| Sharon Bryant <Ot Investment A/C> | 4,372,267 | 1.26% |
| Sharesies Australia Nominee Pty Limited | 4,283,354 | 1.24% |
| HB Biotechnology Ltd | 3,927,899 | 1.14% |
| Mr Barnaby May | 3,272,775 | 0.95% |
| Christopher David Astley Milne | 3,248,022 | 0.94% |
| Mr John Anthony Dell | 3,108,864 | 0.90% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 3,063,242 | 0.89% |
| JK One W One Ltd | 3,041,226 | 0.88% |
